US FDA approval was granted three weeks early for the Regeneron Pharmaceuticals vascular endothelial growth factor (VEGF) inhibitor Eylea (aflibercept) in the treatment of diabetic macular edema (DME), broadening the blockbuster biologic's label beyond its first two indications.
US FDA approval was granted three weeks early for the Regeneron Pharmaceuticals vascular endothelial growth factor (VEGF) inhibitor Eylea (aflibercept) in the treatment of diabetic macular edema (DME), broadening the blockbuster biologic's label beyond its first two indications.
Tarrytown, New York-based Regeneron may add a fourth indication before year-end, since the FDA is expected to decide on a...
The Lyon, France-based company has filed for insolvency and is running out of time to find new funding for its metabolic disease pipeline.
Maziar Mike Doustdar has led the company’s international operations and will succeed Lars Fruergaard Jørgensen on August 7.
In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.
In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists, which analysts expect to grow into a $50bn market opportunity.
Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.
In an interview, chief commercial officer Tolga Tanguler gave some ideas of what to expect as the company prepares to launch the drug for ATTR-CM in Europe.
The Netherlands-headquartered company is enjoying huge success with Vyvgart in two autoimmune conditions, with a new prefilled syringe version reaching more patient groups.
